Elevance Health Earnings Beat, Raises 2026 Outlook

Elevance Health earnings topped expectations, and the insurer raised its full-year outlook in a July 15, 2026 press release, citing stronger sales, disciplined cost control, and lower medical expenses that boosted second-quarter results and allowed management to lift cash-flow targets.

Quarter Results and Guidance

Elevance Health, Inc. (NYSE: ELV) reported second-quarter operating revenue of $49.8 billion, GAAP net income of $1.463 billion, GAAP diluted earnings per share (EPS) of $6.71, and adjusted diluted EPS of $7.45. The adjusted results reflected favorable benefit expense performance and an approximately $0.80 per-share net below-the-line benefit. The company raised its full-year 2026 guidance to at least $20.10 on a GAAP diluted-EPS basis and at least $27.00 on an adjusted basis. It also increased operating cash-flow guidance to $6.0 billion, attributing the revisions to the quarter’s strength.

The company did not disclose new regulatory approvals, enforcement actions, or mergers and acquisitions in the second-quarter materials.

Cost Control and Market Context

Management credited the quarter’s outperformance to disciplined execution and improved operating performance across a diversified portfolio. The company emphasized ongoing focus on medical cost management, member experience, provider connectivity, and operating efficiency.

Analysts had expected EPS in the $6.18–$6.21 range and revenue between $48.45 billion and $48.82 billion. Elevance’s adjusted EPS and revenue exceeded those estimates, with adjusted EPS beating consensus by roughly $1.2 per share and revenue surpassing forecasts by several hundred million dollars.

Secondary data show operating gain narrowed to $1.8 billion from $2.4 billion year-over-year, and operating margin declined to 3.5%, reflecting a mix of operating-level compression and below-the-line items supporting reported earnings.

Elevance framed the guidance increase as a reflection of strong second-quarter operating results and expressed confidence in its medical-cost management and execution across the portfolio. The raised operating cash-flow target signals stronger near-term cash generation and a firmer base for capital deployment planning.

“Our second quarter results exceeded our outlook, supported by disciplined execution and improved operating performance across our diversified portfolio,” the company said in its press release.